

**Information pursuant to Sec. 125 (1), (5) AktG in connection with Article 4 (1) and Table 3 of the Annex to Implementing Regulation (EU) 2018/1212 („Implementing Regulation (EU)“)**

Type of information	Description
<b>A. Specification of the message</b>	
1. Unique identifier of the event	Virtual Annual General Meeting of SCHOTT Pharma AG & Co. KGaA Specification in accordance with Implementing Regulation (EU): 0aadf39a899dee11b52d00505696f23c
2. Type of Message	Convening of the Annual General Meeting Specification in accordance with Implementing Regulation (EU): NEWM
<b>B. Specification of the issuer</b>	
1. ISIN	DE000A3ENQ51
2. Name if the issuer	SCHOTT Pharma AG & Co. KGaA
<b>C. Specification of the meeting</b>	
1. Date of the General Meeting	March 14, 2024 Specification in accordance with Implementing Regulation (EU): 20240314
2. Time of the General Meeting	10:00 (CET) Specification in accordance with Implementing Regulation (EU): 09:00 (UTC)
3. Type of the General Meeting	Annual General Meeting held as a virtual general meeting without the physical presence of shareholders or their representatives (with the exception of the proxies appointed by the Company to exercise voting rights) Specification in accordance with Implementing Regulation (EU): GMET
4. Location of the General Meeting	URL to the Company's InvestorPortal to follow the Annual General Meeting in video and audio and to exercise shareholders' rights: <a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a>

	<p>Location of the Annual General Meeting in accordance with the German Stock Corporation Act:</p> <p>Erich-Schott-Centrum, room E.01-E.02, Hattenbergstraße 10, 55122 Mainz</p>
5. Recod Date	<p>February 21, 2024 (24:00 (CET))</p> <p>Specification in accordance with Implementing Regulation (EU): 20240221, 23:00 (UTC)</p>
6. Uniform Resource Locator (URL)	<p><a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a></p>
<b>D. Participation in the general meeting</b>	
1. Method of participation by shareholder	<p>Access and participation by way of electronic communication via the password-protected InvestorPortal under <a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a></p> <p>Voting rights exercised by voting by mail</p> <p>Voting rights exercised by authorizing and instructing proxies appointed by the Company (also by a proxy)</p> <p>Specification in accordance with Implementing Regulation (EU): VI, EV, PX</p>
2. Issuer deadline for the notification of participation	<p>March 7, 2024, 24:00 (CET)</p> <p>Specification in accordance with Implementing Regulation (EU): 20240307; 23:00 (UTC)</p>
3. Issuer deadline for voting	<p><u>The exercise of voting rights by way of voting by mail,</u></p> <ul style="list-style-type: none"> <li>via the password-protected InvestorPortal under <a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a> not later than the closing of voting on the agenda by the chairman of the meeting in the Annual General Meeting on March 14, 2024</li> </ul> <p>Specification in accordance with Implementing Regulation (EU): 20240314; until closing of the voting</p> <ul style="list-style-type: none"> <li>by mail or by e-mail: not later than March 13, 2024, 24:00 (CET).</li> </ul> <p>Specification in accordance with Implementing Regulation (EU): 20240313; 23:00 (UTC)</p> <p><u>Exercising voting rights by granting power of attorney and issuing instructions to the proxies appointed by the Company,</u></p> <ul style="list-style-type: none"> <li>via the password-protected InvestorPortal under <a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a> not later than</li> </ul>

	<p>the time announced by the chairman of the meeting for the respective voting to close the possibility of issuing proxies and instructions at the Annual General Meeting on March 14, 2024</p> <p>Specification in accordance with Implementing Regulation (EU): 20240314; not later than the time announced by the chairman of the meeting for the respective voting to close the possibility of issuing proxies and instructions</p> <ul style="list-style-type: none"> <li>• by mail or by e-mail: not later than March 13, 2024, 24:00 (CET).</li> </ul> <p>Specification in accordance with Implementing Regulation (EU): 20240313; 23:00 (UTC)</p>
<b>E. Agenda</b>	
<b>E. Agenda – Agenda Item 1</b>	
1. Unique identifier of the agenda item	1
2. Title of the agenda item	<p>Presentation of the annual financial statements and consolidated financial statements of SCHOTT Pharma AG &amp; Co. KGaA, each approved by the Supervisory Board, the combined management report for SCHOTT Pharma AG &amp; Co. KGaA and the Group, the explanatory report of the General Partner on the information pursuant to sections 289a and 315a of the German Commercial Code (Handelsgesetzbuch – HGB) and the report of the Supervisory Board of SCHOTT Pharma AG &amp; Co. KGaA, each for fiscal year 2022/2023; resolution on the adoption of the annual financial statements of SCHOTT Pharma AG &amp; Co. KGaA for fiscal year 2022/2023</p>
3. Uniform Resource Locator (URL) of the materials	<a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a>
4. Vote	<p>Binding Vote</p> <p>Specification in accordance with Implementing Regulation (EU): BV</p>
5. Alternative voting options	<p>Vote in favour; vote against; abstention</p> <p>Specification in accordance with Implementing Regulation (EU): VF, VA, AB</p>

<b>E. Agenda – Agenda Item 2</b>	
1. Unique identifier of the agenda item	2
2. Title of the agenda item	Resolution on the allocation of distributable profit
3. Uniform Resource Locator (URL) of the materials	<a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a>
4. Vote	Binding Vote Specification in accordance with Implementing Regulation (EU): BV
5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB
<b>E. Agenda – Agenda Item 3</b>	
1. Unique identifier of the agenda item	3
2. Title of the agenda item	Resolution on the approval of the actions of the General Partner for fiscal year 2022/2023
3. Uniform Resource Locator (URL) of the materials	<a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a>
4. Vote	Binding Vote Specification in accordance with Implementing Regulation (EU): BV
5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB
<b>E. Agenda – Agenda Item 4</b>	
1. Unique identifier of the agenda item	4
2. Title of the agenda item	Resolution on the approval of the actions of the Supervisory Board for fiscal year 2022/2023
3. Uniform Resource Locator (URL) of the materials	<a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a>

4. Vote	Binding Vote Specification in accordance with Implementing Regulation (EU): BV
5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB
<b>E. Agenda – Agenda Item 5</b>	
1. Unique identifier of the agenda item	5
2. Title of the agenda item	Election of the auditor and the Group auditor for fiscal year 2023/2024 as well as the auditor for the potential review of the condensed financial statements and the interim management report for fiscal year 2023/2024 and other interim financial information
3. Uniform Resource Locator (URL) of the materials	<a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a>
4. Vote	Binding Vote Specification in accordance with Implementing Regulation (EU): BV
5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB
<b>E. Agenda – Agenda Item 6</b>	
1. Unique identifier of the agenda item	6
2. Title of the agenda item	Resolution on the approval of the remuneration report for fiscal year 2022/2023
3. Uniform Resource Locator (URL) of the materials	<a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a>
4. Vote	Advisory Vote Specification in accordance with Implementing Regulation (EU): AV
5. Alternative voting options	Vote in favour; vote against; abstention

	Specification in accordance with Implementing Regulation (EU): VF, VA, AB
<b>E. Agenda – Agenda Item 7</b>	
1. Unique identifier of the agenda item	7
2. Title of the agenda item	Resolution on the approval of the remuneration system for the members of the Management Board of the General Partner
3. Uniform Resource Locator (URL) of the materials	<a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a>
4. Vote	Advisory Vote Specification in accordance with Implementing Regulation (EU): AV
5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB
<b>E. Agenda – Agenda Item 8</b>	
1. Unique identifier of the agenda item	8
2. Title of the agenda item	Resolution on the confirmation of the remuneration and on the remuneration system for the members of the Supervisory Board
3. Uniform Resource Locator (URL) of the materials	<a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a>
4. Vote	Binding Vote Specification in accordance with Implementing Regulation (EU): BV
5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB
<b>E. Agenda – Agenda Item 9</b>	
1. Unique identifier of the agenda item	9

2. Title of the agenda item	Resolution on the amendment of Article 17 (4) of the Company's Articles of Association (record date)
3. Uniform Resource Locator (URL) of the materials	<a href="https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/">https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</a>
4. Vote	Binding Vote Specification in accordance with Implementing Regulation (EU): BV
5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB
<b>F. Specification of the deadlines regarding the exercise of other shareholders rights</b>	
<b>F. Shareholder Right – Requests for amendments to the agenda pursuant to sec. 278 (3), 122 (2) AktG</b>	
1. Object of deadline	Submission of the request for amendments of the agenda
2. Applicable issuer deadline	February 12, 2024, 24:00 (CET) Specification in accordance with Implementing Regulation (EU): 20240212; 23:00 (UTC)
<b>F. Shareholder Right – Countermotions pursuant to sec. 278 (3), 126, 118a (1), sentence 2 no. 3, 130a (5) sentence 3 AktG</b>	
1. Object of deadline	Submission of countermotions on specific items on the agenda
2. Applicable issuer deadline	February 28, 2024, 24:00 (CET) Specification in accordance with Implementing Regulation (EU): 20240228; 23:00 (UTC)
<b>F. Shareholder Right – Election proposals pursuant to sec. 278 (3), 127, 118a (1), sentence 2 no. 3, 130a (5) sentence 3 AktG</b>	
1. Object of deadline	Transmission of the election proposal for the election of auditors
2. Applicable issuer deadline	February 28, 2024, 24:00 (CET) Specification in accordance with Implementing Regulation (EU): 20240228; 23:00 (UTC)
<b>F. Shareholder Right – Right to submit statements pursuant to sec. 278 (3), 118a (1), sentence 2 no. 6, 130a (1) to (4) AktG</b>	

1. Object of deadline	Submission of statements on agenda items by way of electronic communication via the E-Mail Stellungnahme.Pharma@schott.com
2. Applicable issuer deadline	March 8, 2024, 24:00 (CET) Specification in accordance with Implementing Regulation (EU): 20240308; 23:00 (UTC)
<b>F. Shareholder Right – Right to speak pursuant to sec. 278 (3), 118a (1), sentence 2 no. 7, 130a (5) and (6) AktG</b>	
1. Object of deadline	Right to speak at the Annual General Meeting by way of video communication via the InvestorPortal
2. Applicable issuer deadline	on March 14, 2024 during the Annual General Meeting Specification in accordance with Implementing Regulation (EU): 20240314 according to the instructions of the chairman of the meeting during the Annual General Meeting
<b>F. Shareholder Right – Right to propose motions at the Annual General Meeting</b>	
1. Object of deadline	Submitting motions and election proposals by way of video communication via the InvestorPortal
2. Applicable issuer deadline	on March 14, 2024 during the Annual General Meeting Specification in accordance with Implementing Regulation (EU): 20240314 according to the instructions of the chairman of the meeting during the Annual General Meeting
<b>F. Shareholder Right – Right to information pursuant to sec. 278 (3), 118a (1), sentence 2 no. 4, 131 AktG</b>	
1. Object of deadline	Right to obtain information at the Annual General Meeting by way of video communication via the InvestorPortal
2. Applicable issuer deadline	on March 14, 2024 during the Annual General Meeting Specification in accordance with Implementing Regulation (EU): 20240314 according to the instructions of the chairman of the meeting during the Annual General Meeting
<b>F. Shareholder Right – Request pursuant to sec. 278 (3), 118a (1), sentence 2 no. 4, 131 (4) sentence 1, 2 AktG</b>	
1. Object of deadline	Submission of requests pursuant to sec. 278 (3), 118a (1), sentence 2 no. 4, 131 (4) sentence 1, 2 AktG by way of electronic communication via the InvestorPortal
2. Applicable issuer deadline	on March 14, 2024 during the Annual General Meeting Specification in accordance with Implementing Regulation (EU): 20240314 according to the instructions of the chairman of the meeting during the Annual General Meeting



<b>F. Shareholder Right – Requests pursuant to sec. 278 (3), 118a (1), sentence 2 no. 4, 131 (5) AktG</b>	
1. Object of deadline	Submission of requests pursuant to sec. 278 (3), 118a (1), sentence 2 no. 4, 131 (5) AktG by way of electronic communication via the InvestorPortal
2. Applicable issuer deadline	on March 14, 2024 during the Annual General Meeting Specification in accordance with Implementing Regulation (EU): 20240314 according to the instructions of the chairman of the meeting during the Annual General Meeting
<b>F. Shareholder Right – Objection to resolutions of the Annual General Meeting</b>	
1. Object of deadline	Filing of objections to resolutions of the Annual General Meeting by way of electronic communication via the InvestorPortal pursuant to sec. 278 (3), 118a (1), sentence 2 no. 8, 245 AktG
2. Applicable issuer deadline	on March 14, 2024 from the beginning of the Annual General Meeting until the closing of the Annual General Meeting by the chairman of the meeting Specification in accordance with Implementing Regulation (EU): 20240314 from the beginning of the Annual General Meeting until the closing of the Annual General Meeting by the chairman of the meeting